XML 120 R101.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Guarantor Financial Information , Consolidating Statement of Comprehensive Income (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Apr. 28, 2017 | Jan. 27, 2017 | Oct. 28, 2016 | Jul. 29, 2016 | Apr. 29, 2016 | Jan. 29, 2016 | Oct. 30, 2015 | Jul. 31, 2015 | Apr. 28, 2017 | Apr. 29, 2016 | Apr. 24, 2015
Condensed Statement of Income Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales | $ 7,916 | $ 7,283 | $ 7,345 | $ 7,166 | $ 7,567 | $ 6,934 | $ 7,058 | $ 7,274 | $ 29,710 | $ 28,833 | $ 20,261
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  |  |  |  | 9,291 | 9,142 | 6,309
Research and development expense |  |  |  |  |  |  |  |  | 2,193 | 2,224 | 1,640
Selling, general, and administrative expense |  |  |  |  |  |  |  |  | 9,711 | 9,469 | 6,904
Special charge (gain), net |  |  |  |  |  |  |  |  | 100 | 70 | (38)
Restructuring charges, net |  |  |  |  |  |  |  |  | 363 | 290 | 237
Certain litigation charges |  |  |  |  |  |  |  |  | 300 | 26 | 42
Acquisition-related items |  |  |  |  |  |  |  |  | 220 | 283 | 550
Amortization of intangible assets |  |  |  |  |  |  |  |  | 1,980 | 1,931 | 733
Other expense, net |  |  |  |  |  |  |  |  | 222 | 107 | 118
Operating profit |  |  |  |  |  |  |  |  | 5,330 | 5,291 | 3,766
Interest income |  |  |  |  |  |  |  |  | (366) | (431) | (386)
Interest expense |  |  |  |  |  |  |  |  | 1,094 | 1,386 | 666
Interest expense, net |  |  |  |  |  |  |  |  | 728 | 955 | 280
Equity in net (income) loss of subsidiaries |  |  |  |  |  |  |  |  | 0 | 0 | 0
Income before provision for income taxes |  |  |  |  |  |  |  |  | 4,602 | 4,336 | 3,486
Provision for income taxes |  |  |  |  |  |  |  |  | 578 | 798 | 811
Net income | 1,164 | 820 | 1,111 | 929 | 1,104 | 1,095 | 520 | 820 | 4,024 | 3,538 | 2,675
Net loss attributable to noncontrolling interests |  |  |  |  |  |  |  |  | 4 | 0 | 0
Net income attributable to Medtronic | $ 1,163 | $ 821 | $ 1,115 | $ 929 | $ 1,104 | $ 1,095 | $ 520 | $ 820 | 4,028 | 3,538 | 2,675
Other comprehensive loss |  |  |  |  |  |  |  |  | (744) | (684) | (587)
Other comprehensive loss attributable to non-controlling interests |  |  |  |  |  |  |  |  | 3 |  |
Other comprehensive (loss) income, net of tax |  |  |  |  |  |  |  |  |  | (684) | (587)
Comprehensive income attributable to Medtronic |  |  |  |  |  |  |  |  | 3,283 | 2,854 | 2,088
Consolidating Adjustments | Medtronic Notes |  |  |  |  |  |  |  |  |  |  |
Condensed Statement of Income Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | (1,294) | (1,410) | (1,261)
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  |  |  |  | (1,317) | (1,410) | (1,245)
Research and development expense |  |  |  |  |  |  |  |  | 0 | 0 | 0
Selling, general, and administrative expense |  |  |  |  |  |  |  |  | 0 | 0 | 0
Special charge (gain), net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Restructuring charges, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Certain litigation charges |  |  |  |  |  |  |  |  | 0 | 0 | 0
Acquisition-related items |  |  |  |  |  |  |  |  | 0 | 0 | 0
Amortization of intangible assets |  |  |  |  |  |  |  |  | 0 | 0 | 0
Other expense, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Operating profit |  |  |  |  |  |  |  |  | 23 | 0 | (16)
Interest income |  |  |  |  |  |  |  |  | 1,598 | 960 | 227
Interest expense |  |  |  |  |  |  |  |  | (1,598) | (960) | (227)
Interest expense, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Equity in net (income) loss of subsidiaries |  |  |  |  |  |  |  |  | 10,223 | 9,103 | 10,910
Income before provision for income taxes |  |  |  |  |  |  |  |  | (10,200) | (9,103) | (10,926)
Provision for income taxes |  |  |  |  |  |  |  |  | 0 | 0 | 0
Net income |  |  |  |  |  |  |  |  | (10,200) |  |
Net loss attributable to noncontrolling interests |  |  |  |  |  |  |  |  | 0 |  |
Net income attributable to Medtronic |  |  |  |  |  |  |  |  | (10,200) | (9,103) | (10,926)
Other comprehensive loss |  |  |  |  |  |  |  |  | 1,563 |  |
Other comprehensive loss attributable to non-controlling interests |  |  |  |  |  |  |  |  | 0 |  |
Other comprehensive (loss) income, net of tax |  |  |  |  |  |  |  |  |  | 1,850 | 1,361
Comprehensive income attributable to Medtronic |  |  |  |  |  |  |  |  | (8,637) | (7,253) | (9,565)
Consolidating Adjustments | CIFSA Senior Notes |  |  |  |  |  |  |  |  |  |  |
Condensed Statement of Income Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 0 | 0 | 0
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  |  |  |  | 0 | 0 | 0
Research and development expense |  |  |  |  |  |  |  |  | 0 | 0 | 0
Selling, general, and administrative expense |  |  |  |  |  |  |  |  | 0 | 0 | 0
Special charge (gain), net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Restructuring charges, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Certain litigation charges |  |  |  |  |  |  |  |  | 0 | 0 | 0
Acquisition-related items |  |  |  |  |  |  |  |  | 0 | 0 | 0
Amortization of intangible assets |  |  |  |  |  |  |  |  | 0 | 0 | 0
Other expense, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Operating profit |  |  |  |  |  |  |  |  | 0 | 0 | 0
Interest income |  |  |  |  |  |  |  |  | 805 | 1,177 | 319
Interest expense |  |  |  |  |  |  |  |  | (805) | (1,177) | (319)
Interest expense, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Equity in net (income) loss of subsidiaries |  |  |  |  |  |  |  |  | 10,067 | 8,680 | 4,372
Income before provision for income taxes |  |  |  |  |  |  |  |  | (10,067) | (8,680) | (4,372)
Provision for income taxes |  |  |  |  |  |  |  |  | 0 | 0 | 0
Net income |  |  |  |  |  |  |  |  | (10,067) |  |
Net loss attributable to noncontrolling interests |  |  |  |  |  |  |  |  | 0 |  |
Net income attributable to Medtronic |  |  |  |  |  |  |  |  | (10,067) | (8,680) | (4,372)
Other comprehensive loss |  |  |  |  |  |  |  |  | 1,574 |  |
Other comprehensive loss attributable to non-controlling interests |  |  |  |  |  |  |  |  | 0 |  |
Other comprehensive (loss) income, net of tax |  |  |  |  |  |  |  |  |  | 1,470 | 974
Comprehensive income attributable to Medtronic |  |  |  |  |  |  |  |  | (8,493) | (7,210) | (3,398)
Medtronic plc | Medtronic Notes |  |  |  |  |  |  |  |  |  |  |
Condensed Statement of Income Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 0 | 0 | 0
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  |  |  |  | 0 | 0 | 0
Research and development expense |  |  |  |  |  |  |  |  | 0 | 0 | 0
Selling, general, and administrative expense |  |  |  |  |  |  |  |  | 12 | 10 | 1
Special charge (gain), net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Restructuring charges, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Certain litigation charges |  |  |  |  |  |  |  |  | 0 | 0 | 0
Acquisition-related items |  |  |  |  |  |  |  |  | 0 | 0 | 0
Amortization of intangible assets |  |  |  |  |  |  |  |  | 0 | 0 | 0
Other expense, net |  |  |  |  |  |  |  |  | 18 | 112 | 103
Operating profit |  |  |  |  |  |  |  |  | (30) | (122) | (104)
Interest income |  |  |  |  |  |  |  |  | 0 | 0 | 0
Interest expense |  |  |  |  |  |  |  |  | 113 | 25 | 0
Interest expense, net |  |  |  |  |  |  |  |  | 113 | 25 | 0
Equity in net (income) loss of subsidiaries |  |  |  |  |  |  |  |  | (4,163) | (3,676) | (2,790)
Income before provision for income taxes |  |  |  |  |  |  |  |  | 4,020 | 3,529 | 2,686
Provision for income taxes |  |  |  |  |  |  |  |  | (8) | (9) | 11
Net income |  |  |  |  |  |  |  |  | 4,028 |  |
Net loss attributable to noncontrolling interests |  |  |  |  |  |  |  |  | 0 |  |
Net income attributable to Medtronic |  |  |  |  |  |  |  |  | 4,028 | 3,538 | 2,675
Other comprehensive loss |  |  |  |  |  |  |  |  | (745) |  |
Other comprehensive loss attributable to non-controlling interests |  |  |  |  |  |  |  |  | 0 |  |
Other comprehensive (loss) income, net of tax |  |  |  |  |  |  |  |  |  | (684) | (587)
Comprehensive income attributable to Medtronic |  |  |  |  |  |  |  |  | 3,283 | 2,854 | 2,088
Medtronic plc | CIFSA Senior Notes |  |  |  |  |  |  |  |  |  |  |
Condensed Statement of Income Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 0 | 0 | 0
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  |  |  |  | 0 | 0 | 0
Research and development expense |  |  |  |  |  |  |  |  | 0 | 0 | 0
Selling, general, and administrative expense |  |  |  |  |  |  |  |  | 12 | 10 | 1
Special charge (gain), net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Restructuring charges, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Certain litigation charges |  |  |  |  |  |  |  |  | 0 | 0 | 0
Acquisition-related items |  |  |  |  |  |  |  |  | 0 | 0 | 0
Amortization of intangible assets |  |  |  |  |  |  |  |  | 0 | 0 | 0
Other expense, net |  |  |  |  |  |  |  |  | 18 | 112 | 103
Operating profit |  |  |  |  |  |  |  |  | (30) | (122) | (104)
Interest income |  |  |  |  |  |  |  |  | 0 | 0 | 0
Interest expense |  |  |  |  |  |  |  |  | 113 | 25 | 0
Interest expense, net |  |  |  |  |  |  |  |  | 113 | 25 | 0
Equity in net (income) loss of subsidiaries |  |  |  |  |  |  |  |  | (4,163) | (3,676) | (2,790)
Income before provision for income taxes |  |  |  |  |  |  |  |  | 4,020 | 3,529 | 2,686
Provision for income taxes |  |  |  |  |  |  |  |  | (8) | (9) | 11
Net income |  |  |  |  |  |  |  |  | 4,028 |  |
Net loss attributable to noncontrolling interests |  |  |  |  |  |  |  |  | 0 |  |
Net income attributable to Medtronic |  |  |  |  |  |  |  |  | 4,028 | 3,538 | 2,675
Other comprehensive loss |  |  |  |  |  |  |  |  | (745) |  |
Other comprehensive loss attributable to non-controlling interests |  |  |  |  |  |  |  |  | 0 |  |
Other comprehensive (loss) income, net of tax |  |  |  |  |  |  |  |  |  | (684) | (587)
Comprehensive income attributable to Medtronic |  |  |  |  |  |  |  |  | 3,283 | 2,854 | 2,088
Subsidiary Issuer | Medtronic Notes |  |  |  |  |  |  |  |  |  |  |
Condensed Statement of Income Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 1,296 | 1,411 | 1,261
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  |  |  |  | 932 | 991 | 895
Research and development expense |  |  |  |  |  |  |  |  | 636 | 627 | 552
Selling, general, and administrative expense |  |  |  |  |  |  |  |  | 1,163 | 991 | 857
Special charge (gain), net |  |  |  |  |  |  |  |  | 100 | 70 | 100
Restructuring charges, net |  |  |  |  |  |  |  |  | 114 | 17 | 7
Certain litigation charges |  |  |  |  |  |  |  |  | 0 | 0 | 0
Acquisition-related items |  |  |  |  |  |  |  |  | 133 | 135 | 312
Amortization of intangible assets |  |  |  |  |  |  |  |  | 11 | 12 | 11
Other expense, net |  |  |  |  |  |  |  |  | (2,954) | (2,329) | (1,618)
Operating profit |  |  |  |  |  |  |  |  | 1,161 | 897 | 145
Interest income |  |  |  |  |  |  |  |  | (250) | (237) | (56)
Interest expense |  |  |  |  |  |  |  |  | 1,652 | 1,906 | 762
Interest expense, net |  |  |  |  |  |  |  |  | 1,402 | 1,669 | 706
Equity in net (income) loss of subsidiaries |  |  |  |  |  |  |  |  | (2,484) | (2,447) | (5,500)
Income before provision for income taxes |  |  |  |  |  |  |  |  | 2,243 | 1,675 | 4,939
Provision for income taxes |  |  |  |  |  |  |  |  | (1) | (96) | (44)
Net income |  |  |  |  |  |  |  |  | 2,244 |  |
Net loss attributable to noncontrolling interests |  |  |  |  |  |  |  |  | 0 |  |
Net income attributable to Medtronic |  |  |  |  |  |  |  |  | 2,244 | 1,771 | 4,983
Other comprehensive loss |  |  |  |  |  |  |  |  | 111 |  |
Other comprehensive loss attributable to non-controlling interests |  |  |  |  |  |  |  |  | 0 |  |
Other comprehensive (loss) income, net of tax |  |  |  |  |  |  |  |  |  | (493) | (542)
Comprehensive income attributable to Medtronic |  |  |  |  |  |  |  |  | 2,355 | 1,278 | 4,441
Subsidiary Issuer | CIFSA Senior Notes |  |  |  |  |  |  |  |  |  |  |
Condensed Statement of Income Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 0 | 0 | 0
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  |  |  |  | 0 | 0 | 0
Research and development expense |  |  |  |  |  |  |  |  | 0 | 0 | 0
Selling, general, and administrative expense |  |  |  |  |  |  |  |  | 1 | 1 | 0
Special charge (gain), net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Restructuring charges, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Certain litigation charges |  |  |  |  |  |  |  |  | 0 | 0 | 0
Acquisition-related items |  |  |  |  |  |  |  |  | 0 | 0 | 0
Amortization of intangible assets |  |  |  |  |  |  |  |  | 0 | 0 | 0
Other expense, net |  |  |  |  |  |  |  |  | 1 | 1 | 0
Operating profit |  |  |  |  |  |  |  |  | (2) | (2) | 0
Interest income |  |  |  |  |  |  |  |  | (82) | (434) | (149)
Interest expense |  |  |  |  |  |  |  |  | 104 | 138 | 29
Interest expense, net |  |  |  |  |  |  |  |  | 22 | (296) | (120)
Equity in net (income) loss of subsidiaries |  |  |  |  |  |  |  |  | (2,329) | (2,043) | 1,085
Income before provision for income taxes |  |  |  |  |  |  |  |  | 2,305 | 2,337 | (965)
Provision for income taxes |  |  |  |  |  |  |  |  | 0 | 0 | 0
Net income |  |  |  |  |  |  |  |  | 2,305 |  |
Net loss attributable to noncontrolling interests |  |  |  |  |  |  |  |  | 0 |  |
Net income attributable to Medtronic |  |  |  |  |  |  |  |  | 2,305 | 2,337 | (965)
Other comprehensive loss |  |  |  |  |  |  |  |  | (84) |  |
Other comprehensive loss attributable to non-controlling interests |  |  |  |  |  |  |  |  | 0 |  |
Other comprehensive (loss) income, net of tax |  |  |  |  |  |  |  |  |  | (102) | 200
Comprehensive income attributable to Medtronic |  |  |  |  |  |  |  |  | 2,221 | 2,235 | (765)
Subsidiary Guarantors | Medtronic Notes |  |  |  |  |  |  |  |  |  |  |
Condensed Statement of Income Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 0 | 0 | 0
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  |  |  |  | 0 | 0 | 0
Research and development expense |  |  |  |  |  |  |  |  | 0 | 0 | 0
Selling, general, and administrative expense |  |  |  |  |  |  |  |  | 0 | 0 | 0
Special charge (gain), net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Restructuring charges, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Certain litigation charges |  |  |  |  |  |  |  |  | 0 | 0 | 0
Acquisition-related items |  |  |  |  |  |  |  |  | 0 | 0 | 0
Amortization of intangible assets |  |  |  |  |  |  |  |  | 0 | 0 | 0
Other expense, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Operating profit |  |  |  |  |  |  |  |  | 0 | 0 | 0
Interest income |  |  |  |  |  |  |  |  | (649) | (706) | (170)
Interest expense |  |  |  |  |  |  |  |  | 62 | 10 | 0
Interest expense, net |  |  |  |  |  |  |  |  | (587) | (696) | (170)
Equity in net (income) loss of subsidiaries |  |  |  |  |  |  |  |  | (3,576) | (2,980) | (2,620)
Income before provision for income taxes |  |  |  |  |  |  |  |  | 4,163 | 3,676 | 2,790
Provision for income taxes |  |  |  |  |  |  |  |  | 0 | 0 | 0
Net income |  |  |  |  |  |  |  |  | 4,163 |  |
Net loss attributable to noncontrolling interests |  |  |  |  |  |  |  |  | 0 |  |
Net income attributable to Medtronic |  |  |  |  |  |  |  |  | 4,163 | 3,676 | 2,790
Other comprehensive loss |  |  |  |  |  |  |  |  | (745) |  |
Other comprehensive loss attributable to non-controlling interests |  |  |  |  |  |  |  |  | 0 |  |
Other comprehensive (loss) income, net of tax |  |  |  |  |  |  |  |  |  | (684) | (587)
Comprehensive income attributable to Medtronic |  |  |  |  |  |  |  |  | 3,418 | 2,992 | 2,203
Subsidiary Guarantors | CIFSA Senior Notes |  |  |  |  |  |  |  |  |  |  |
Condensed Statement of Income Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 0 | 0 | 0
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  |  |  |  | 0 | 0 | 0
Research and development expense |  |  |  |  |  |  |  |  | 0 | 0 | 0
Selling, general, and administrative expense |  |  |  |  |  |  |  |  | 2 | 3 | 21
Special charge (gain), net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Restructuring charges, net |  |  |  |  |  |  |  |  | 0 | 0 | 0
Certain litigation charges |  |  |  |  |  |  |  |  | 0 | 0 | 0
Acquisition-related items |  |  |  |  |  |  |  |  | 0 | 0 | 0
Amortization of intangible assets |  |  |  |  |  |  |  |  | 0 | 0 | 0
Other expense, net |  |  |  |  |  |  |  |  | 4 | (18) | 26
Operating profit |  |  |  |  |  |  |  |  | (6) | 15 | (47)
Interest income |  |  |  |  |  |  |  |  | (656) | (710) | (170)
Interest expense |  |  |  |  |  |  |  |  | 62 | 10 | 0
Interest expense, net |  |  |  |  |  |  |  |  | (594) | (700) | (170)
Equity in net (income) loss of subsidiaries |  |  |  |  |  |  |  |  | (3,575) | (2,961) | (2,667)
Income before provision for income taxes |  |  |  |  |  |  |  |  | 4,163 | 3,676 | 2,790
Provision for income taxes |  |  |  |  |  |  |  |  | 0 | 0 | 0
Net income |  |  |  |  |  |  |  |  | 4,163 |  |
Net loss attributable to noncontrolling interests |  |  |  |  |  |  |  |  | 0 |  |
Net income attributable to Medtronic |  |  |  |  |  |  |  |  | 4,163 | 3,676 | 2,790
Other comprehensive loss |  |  |  |  |  |  |  |  | (745) |  |
Other comprehensive loss attributable to non-controlling interests |  |  |  |  |  |  |  |  | 0 |  |
Other comprehensive (loss) income, net of tax |  |  |  |  |  |  |  |  |  | (684) | (587)
Comprehensive income attributable to Medtronic |  |  |  |  |  |  |  |  | 3,418 | 2,992 | 2,203
Subsidiary Non-guarantors | Medtronic Notes |  |  |  |  |  |  |  |  |  |  |
Condensed Statement of Income Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 29,708 | 28,832 | 20,261
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  |  |  |  | 9,676 | 9,561 | 6,659
Research and development expense |  |  |  |  |  |  |  |  | 1,557 | 1,597 | 1,088
Selling, general, and administrative expense |  |  |  |  |  |  |  |  | 8,536 | 8,468 | 6,046
Special charge (gain), net |  |  |  |  |  |  |  |  | 0 | 0 | (138)
Restructuring charges, net |  |  |  |  |  |  |  |  | 249 | 273 | 230
Certain litigation charges |  |  |  |  |  |  |  |  | 300 | 26 | 42
Acquisition-related items |  |  |  |  |  |  |  |  | 87 | 148 | 238
Amortization of intangible assets |  |  |  |  |  |  |  |  | 1,969 | 1,919 | 722
Other expense, net |  |  |  |  |  |  |  |  | 3,158 | 2,324 | 1,633
Operating profit |  |  |  |  |  |  |  |  | 4,176 | 4,516 | 3,741
Interest income |  |  |  |  |  |  |  |  | (1,065) | (448) | (387)
Interest expense |  |  |  |  |  |  |  |  | 865 | 405 | 131
Interest expense, net |  |  |  |  |  |  |  |  | (200) | (43) | (256)
Equity in net (income) loss of subsidiaries |  |  |  |  |  |  |  |  | 0 | 0 | 0
Income before provision for income taxes |  |  |  |  |  |  |  |  | 4,376 | 4,559 | 3,997
Provision for income taxes |  |  |  |  |  |  |  |  | 587 | 903 | 844
Net income |  |  |  |  |  |  |  |  | 3,789 |  |
Net loss attributable to noncontrolling interests |  |  |  |  |  |  |  |  | 4 |  |
Net income attributable to Medtronic |  |  |  |  |  |  |  |  | 3,793 | 3,656 | 3,153
Other comprehensive loss |  |  |  |  |  |  |  |  | (928) |  |
Other comprehensive loss attributable to non-controlling interests |  |  |  |  |  |  |  |  | 3 |  |
Other comprehensive (loss) income, net of tax |  |  |  |  |  |  |  |  |  | (673) | (232)
Comprehensive income attributable to Medtronic |  |  |  |  |  |  |  |  | 2,864 | 2,983 | 2,921
Subsidiary Non-guarantors | CIFSA Senior Notes |  |  |  |  |  |  |  |  |  |  |
Condensed Statement of Income Captions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 29,710 | 28,833 | 20,261
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  |  |  |  |  |  |  |  | 9,291 | 9,142 | 6,309
Research and development expense |  |  |  |  |  |  |  |  | 2,193 | 2,224 | 1,640
Selling, general, and administrative expense |  |  |  |  |  |  |  |  | 9,696 | 9,455 | 6,882
Special charge (gain), net |  |  |  |  |  |  |  |  | 100 | 70 | (38)
Restructuring charges, net |  |  |  |  |  |  |  |  | 363 | 290 | 237
Certain litigation charges |  |  |  |  |  |  |  |  | 300 | 26 | 42
Acquisition-related items |  |  |  |  |  |  |  |  | 220 | 283 | 550
Amortization of intangible assets |  |  |  |  |  |  |  |  | 1,980 | 1,931 | 733
Other expense, net |  |  |  |  |  |  |  |  | 199 | 12 | (11)
Operating profit |  |  |  |  |  |  |  |  | 5,368 | 5,400 | 3,917
Interest income |  |  |  |  |  |  |  |  | (433) | (464) | (386)
Interest expense |  |  |  |  |  |  |  |  | 1,620 | 2,390 | 956
Interest expense, net |  |  |  |  |  |  |  |  | 1,187 | 1,926 | 570
Equity in net (income) loss of subsidiaries |  |  |  |  |  |  |  |  | 0 | 0 | 0
Income before provision for income taxes |  |  |  |  |  |  |  |  | 4,181 | 3,474 | 3,347
Provision for income taxes |  |  |  |  |  |  |  |  | 586 | 807 | 800
Net income |  |  |  |  |  |  |  |  | 3,595 |  |
Net loss attributable to noncontrolling interests |  |  |  |  |  |  |  |  | 4 |  |
Net income attributable to Medtronic |  |  |  |  |  |  |  |  | 3,599 | 2,667 | 2,547
Other comprehensive loss |  |  |  |  |  |  |  |  | (744) |  |
Other comprehensive loss attributable to non-controlling interests |  |  |  |  |  |  |  |  | 3 |  |
Other comprehensive (loss) income, net of tax |  |  |  |  |  |  |  |  |  | (684) | (587)
Comprehensive income attributable to Medtronic |  |  |  |  |  |  |  |  | $ 2,854 | $ 1,983 | $ 1,960

X
- Definition The following items are included within acquisition-related items: The change in the fair value of the contingent milestone consideration for the reporting period, certain-related acquisition costs, such as banker fees, legal fees, severance, and other professional fees, and impairment losses of recently acquired in-process research and development (IPR&D). + References No definition available. + Details
Name: | mdt_AcquisitionRelatedGainsCharges
Namespace Prefix: | mdt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses, net of reversals, associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to discontinued operation or an asset retirement obligation. + References No definition available. + Details
Name: | mdt_RestructuringChargesNetofRestructuringReversals
Namespace Prefix: | mdt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Special Charges (Gains) + References No definition available. + Details
Name: | mdt_SpecialChargesGains
Namespace Prefix: | mdt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e557-108580 + Details
Name: | us-gaap_ComprehensiveIncomeNetOfTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CondensedStatementOfIncomeCaptionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CostsAndExpensesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount after tax of income (loss) of subsidiary attributable to the parent entity. + References No definition available. + Details
Name: | us-gaap_IncomeLossFromSubsidiariesNetOfTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeTaxExpenseBenefit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of the cost of borrowed funds accounted for as interest expense. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 + Details
Name: | us-gaap_InterestExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net amount of nonoperating interest income (expense). + References No definition available. + Details
Name: | us-gaap_InterestIncomeExpenseNonoperatingNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of interest income earned from interest bearing assets classified as other. + References No definition available. + Details
Name: | us-gaap_InterestIncomeOther
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyAccrualProvision
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684 + Details
Name: | us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_NonoperatingIncomeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount after tax and reclassification adjustments of other comprehensive income (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669619-108580 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669625-108580 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 55 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=84158357&loc=d3e1436-108581 + Details
Name: | us-gaap_OtherComprehensiveIncomeLossNetOfTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569643-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683 + Details
Name: | us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount after tax of other comprehensive income (loss) attributable to parent entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569643-111683 + Details
Name: | us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684 + Details
Name: | us-gaap_ProfitLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311 + Details
Name: | us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_ConsolidationEliminationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=mdt_GuarantorsMedtronicNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=mdt_CIFSANotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiaryIssuerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=us-gaap_GuarantorSubsidiariesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=us-gaap_NonGuarantorSubsidiariesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |